Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06286657

Xanthohumol and Viral Infections (XL)

The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Infection Viral Infections Virus Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

In this placebo-controlled study, blood is taken on the first day of the study, followed by a 90-day intervention with xanthohumol or a placebo, which is taken twice daily. Blood samples will be taken on day 0, day 45 and day 90. Should the study participants develop a respiratory infection during the study, they will be asked to perform a self-test.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy
  • BMI >18 kg/m² or < 28kg/m²

Exclusion criteria

  • food intolerances
  • food allergies
  • chronic inflammatory diseases
  • metabolic diseases
  • viral or bacterial infections within the last 3 weeks of inclusion
  • intake of immunosuppressive medication
  • severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
  • influenza infection in the "current" flu season

Treatment and study plan

Xanthohumol

Dietary Supplement

Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days

Placebo

Dietary Supplement

Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days

Primary outcomes

  1. Changes in severity and duration of viral infections

    Time frame: 90 days

    Changes in score of Wisconsin Upper Respiratory Symptom Survey

Secondary outcomes

  1. Changes in blood lipid levels

    Time frame: 90 days

    Changes in triglyceride levels (mg/dl) and cholesterol levels (mg/dl)

  2. Changes in cognitive skills

    Time frame: 90 days

    Assessment of cognitive processes using stroop test

Study contacts

Contact information is provided by the study sponsor or research team.

Ina Bergheim, Prof. Dr.

CONTACT

[email protected]

+43-1-4277-54981

Sponsors and collaborators

Lead sponsor

University of Vienna

Other

Registry information

Official study title

Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Feb 29, 2024
Registry last updated
Apr 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.